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University Medical Center, Leiden, The NetherlandsObjective. To evaluate the effect of statins on aneurysm growth in a group of consecutive patients under surveillance for
infrarenal aortic aneurysms (AAA).
Materials andmethods. All patients (59 statin users, 91 non-users) under surveillance between January 2002 and August
2005 with a follow-up for aneurysm growth of at least 12 months and a minimum of three diameter evaluations were
retrospectively included in the analysis. Multiple regression analysis, weighted with the number of observations, was
performed to test the influence of statins on AAA growth rate.
Results. During a median period of 3.1 (1.1–13.1) years the overall mean aneurysm growth rate was 2.95G2.8 mm/year.
Statin users had a 1.16 mm/year lower AAA growth rate compared to non-users (95% CI 0.33–1.99 mm/year). Increased
age was associated with a slower growth (K0.09 mm/year per year, pZ0.003). Female gender (C1.82 mm/year, pZ0.008)
and aneurysm diameter (C0.06 mm/year per mm, pZ0.049) were associated with increased AAA growth. The use of non-
steroidal anti-inflammatory drugs, chronic lung disease, or other cardiovascular risk factors were not independently
associated with AAA growth.
Conclusions. Statins appear to be associated with attenuation of AAA growth, irrespective of other known factors
influencing aneurysm growth.Keywords: Abdominal aortic aneurysm; Growth; Statins.Introduction
Abdominal aortic aneurysm (AAA) occurs frequently
in the elderly population, i.e. a prevalence of 5–7% in
males between 65 and 74 years, increasing to over 10%
in males over 74 years of age.1–3 The overall mortality
from ruptured AAA remains high, i.e. up to 75%, and
preventive elective repair of large AAAs appears to be
the best option.4 Screening for AAA in populations at
increased risk, i.e. elderly males, to detect those who
will benefit from elective repair seems to be safe and
cost-effective.1–5 However, perioperative compli-
cations of elective AAA repair remain a significant
problem despite recent advances such as cardiopro-
tective medication6,7 and endovascular repair.8,9ing author. Prof. Dr Don Poldermans, MD, Department
urgery, Room H 921, Erasmus MC, Dr Molewaterplein
otterdam, The Netherlands.
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slowing of AAA growth, thereby preventing the
AAA to reach a size requiring surgical intervention.
However, the pathogenesis of AAA growth and
factors that determine this growth, leading eventually
to rupture, remain ill-defined. Recently, several studies
were performed to identify risk factors that were
associated with aneurysmal growth on the level of the
human aorta itself using cell cultures obtained by
aortic wall biopsies. Important factors in this respect
are inflammation markers such as interleukin-610,11
and specific matrix metalloproteinases (MMPs) indu-
cing collagen and elastin degradation in the aortic
wall.12 Importantly, drugs with an anti-inflammatory
action such as prostaglandin synthetase inhibitors
reduce the inflammatory response and are associated,
in a case–control study in humans, with a reduced
aneurysm growth rate.13
Statins (3-hydroxy-3-methylglutaryl co-enzyme
A reductase inhibitors) are known to be highlyEur J Vasc Endovasc Surg 32, 21–26 (2006)
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and improve long-term outcome in patients with or at
risk for coronary artery disease. Recently other, so-
called ‘pleiotropic’, effects of statins were described.14
Statins alter the inflammatory status, e.g. a reduction
of IL-6 release, and may modulate the release of
several substances in the arterial wall, including
MMPs.15 Recently, results of animal studies suggested
an association between statin use and suppression of
the development of aortic aneurysms due to these
pleiotropic effects.16
However, so far no data are available on the
influence of statins on growth of abdominal aneur-
ysms in humans. Therefore, we conducted the present
study with the aim to evaluate the effect of statins on
aneurysm growth in a group of consecutive patients
under surveillance for infrarenal aortic aneurysms.MethodsPatient population
The study population was composed of patients who
were under surveillance for infrarenal abdominal
aortic aneurysm at two hospitals, Erasmus Medical
Center in Rotterdam and Reinier de Graaf Gasthuis in
Delft, in The Netherlands between January 2002 and
August 2005. Patients were retrospectively identified
by screening of surgical medical charts. Patients with
an inflammatory (nZ12) or mycotic aneurysm (nZ1)
were excluded from analysis. All patients had a
follow-up for aneurysm growth of at least 12 months.
A minimum of three separate diameter evaluations
was required to calculate aneurysm growth rates. The
Medical Ethics Committee of the Erasmus Medical
Center was informed about the study protocol, and
per institutional practice no official approval was
requested.Patient characteristics
All patients were screened for cardiac risk factors,
including age, hypertension, angina pectoris, previous
myocardial infarction, heart failure, stroke, renal
failure, diabetes mellitus, and symptoms of other
peripheral arterial disease, i.e. intermittent claudica-
tion. Smoking status (never, current, or former) and
presence of chronic obstructive pulmonary disease
(COPD) was noted as well. All prescription and over-
the-counter medications were noted at the time of the
first outpatient clinic visit and were classified as
follows: statins, beta-blockers, aspirin, angiotensinEur J Vasc Endovasc Surg Vol 32, July 2006converting enzyme inhibitors, calcium channel block-
ers; dihydropyridines or non-dihydropyridines, diure-
tics, nitrates, coumarins, digoxin and non-steroidal
anti-inflammatory drugs (NSAIDs). Patients who
started statins during the surveillance period were
analyzed as non-users up to the date statin therapy
was initiated. These patients were excluded from
further analysis after initiation of statin therapy.Follow-up
The protocol in both hospitals was to screen patients
with abdominal aortic aneurysms every 6–12 months
by means of ultrasonography. All ultrasound measure-
ments were performed by either a radiologist or a
trained and skilled sonographer. Inter- and intra-
observer variablity has been estimated, based on
previous studies from our group, at 96 and 98%,
respectively, in our hospital with good reproducibil-
ity.17 The diameter of the aorta was defined as the
maximum anterior–posterior diameter. At each
follow-up visit changes in medication use were
noted. If the diameter of the aortic aneurysm exceeded
5.0 cm, the growth rate was more than 1 cm/year, or
the aneurysm became symptomatic CT angiography
was performed to evaluate the exact diameter and the
possibility of endovascular repair. The results of the
CT scan were not considered in this study. Patients
who required surgery were censored at the last
ultrasonographic measurement prior to surgery.Statistical analysis
Continuous data were expressed as mean (GSD) or
median (Ginterquartile range) and compared using
the Student’s t-test or Mann–Whitney U-test as
appropriate, i.e. whether there was a normal distri-
bution or not. Categorical data are presented as
percent frequencies and differences between pro-
portions were compared using the chi-square test.
The change in maximum AAA diameter was
assumed to be linear over time and modelled using
linear regression analysis. Growth rate of the AAA for
each patient was estimated as the regression coeffi-
cient, using time as the independent variable and
diameter of AAA as the dependent variable. The time
unit was set to 6 months and this growth rate was then
doubled to give AAA growth rate in millimeter per
year.
Multiple regression analysis was performed to test
the influence of statins on AAA growth rate. In linear
regression analysis annual growth rate was the
dependent variable and age, gender, AAA diameter
Table 1. Clinical baseline characteristic at first screening visit
Total (NZ150) Statin users (NZ59) Non-users (NZ91) p-Value
Males, no. (%) 126 (88) 51 (91) 75 (86) 0.44
Age, years (SD) 69 (7.6) 69 (7.8) 69 (7.5) 0.94
AAA diameter, mm (SD) 38 (7.7) 40 (8.5) 37 (7.0) 0.02
Medical history
Mycardial infarction, no. (%) 47 (31) 18 (30) 29 (32) 0.86
Angina pectoris, no. (%) 27 (18) 12 (20) 15 (17) 0.83
Congestive heart failure, no. (%) 11 (7) 6 (10) 5 (5) 0.36
CVA or TIA, no. (%) 19 (13) 8 (13) 11 (13) 1.0
Diabetes mellitus, no. (%) 19 (13) 9 (16) 10 (11) 0.32
Renal failure, no. (%) 7 (5) 5 (9) 2 (2) 0.11
Hypertension, no. (%) 64 (43) 28 (48) 36 (39) 0.30
COPD, no. (%) 41 (27) 17 (29) 24 (26) 0.85
Intermittent claudication, no. (%) 26 (17) 17 (29) 9 (10) 0.01
Smoking, no. (%) 106 (71) 40 (68) 66 (72) 0.72
AAA, abdominal aortic aneurysm; CVA, cerebrovascular accident; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary
disease.
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cardiovascular risk factors were used as independent
variables. The analysis was weighted with the number
of observations (i.e. number of ultrasound measure-
ments) for each patient. The limit of statistical
significance was set at pZ0.05 (two sided). All analysis
was performed using the statistical software SPSS for
Windows 12.1 (SPSS Inc., Chicago, Illinois, USA).ResultsBaseline characteristics
The study population consisted of 150 patients (88%
men). Mean age at first presentation was 69G7.6 years.
In total, 59 patients (39%) were chronic statin users. Of
these 59 statin users, 24 were on simvastatin, 19 on
atorvastatin, 11 on fluvastatin, and five patients
received pravastatin therapy. Baseline patient charac-
teristics are shown in Table 1. There were no
significant differences in medical history between
groups, except for the presence of intermittent
claudication (29% in statin users vs 10% in non-users,Table 2. Medication use
Total (NZ150)
NSAID, no. (%) 60 (40)
Warfarin derivatives, no. (%) 23 (15)
Beta-blockers, no. (%) 53 (35)
ACE inhibitors, no. (%) 38 (25)
Diuretics, no. (%) 35 (23)
Calcium antagonists, no. (%) 30 (21)
Nitrates, no. (%) 21 (14)
Angiotensin II antagonists, no. (%) 9 (6)
Insulin or oral antidiabetic therapy, no. (%) 19 (13)
Pulmonary medication, no. (%) 21 (14)
NSAID, non-steroidal anti-inflammatory drugs; ACE, angiotensin convpZ0.007). Concomitant medication use is presented in
Table 2. Statin users more often were on warfarin
derivatives (23 vs 10%, pZ0.03) and angiotensin II
antagonists (16 vs 0%, p!0.001). The mean maximum
diameter at first presentation of the AAA was 38G
7.7 mm. Statin users had a significantly larger aneur-
ysm at first presentation (40 vs 37 mm, pZ0.02).Follow-up
Patients were under surveillance for a median
period of 3.1 years (range 1.1–13.1), 2.9 years for
statin users and 3.2 years for non-users (pZ0.49),
with the number of ultrasound examinations vary-
ing from 3 to 12 with a mean of 4.7 measurements
per patient (4.6 in users and 4.7 in non-users, pZ
0.89). The overall mean aneurysm growth rate
during follow-up was 2.95G2.8 mm/year. Six
patients had a negative value of annual aneurysm
growth rate (three non-users and three users). All of
these patients were included in the analysis.
Exclusion of these patients did not result in
significant alteration of the results.Statin users (NZ59) Non-users (NZ91) p-Value
27 (45) 33 (37) 0.38
14 (23) 9 (10)* 0.03
24 (41) 29 (32) 0.28
12 (20) 26 (29) 0.24
18 (30) 17 (19) 0.11
12 (21) 18 (21) 1.0
9 (16) 12 (13) 0.63
9 (16) 0 0.01
9 (16) 10 (11) 0.32
6 (11) 15 (16) 0.38
erting enzyme.
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Table 3. Adjusted (corrected for other factors in the table) estimated difference in mean annual AAA growth
Adj. estimated
difference (mm/year)
95% Confidence interval p-Value
Lower bound Upper bound
Age (per year increase) K0.09 K0.14 K0.03 0.003
Female C1.82 3.15 0.49 0.008
AAA diameter at first screening (per mm increase) C0.06 0.01 0.11 0.049
Intermittent claudication K0.89 K1.89 0.11 0.082
Diabetes mellitus K0.01 K1.25 1.24 0.989
COPD C0.70 K0.24 1.64 0.145
Statin use K1.16 K1.99 K0.33 0.006
NSAID use K0.13 K0.97 0.70 0.754














O. Schouten et al.24Univariate analyses
In univariate analysis statin use was associated with a
significant attenuation of aneurysm growth (pZ0.001
(Fig. 1)). Increasing age and intermittent claudication
(pZ0.02) also were associated with an attenuation of
AAA growth rate. Other potential factors, such as
diabetes mellitus, COPD, AAA diameter at first
presentation or other medication use (in particular
NSAID use), were not associated with a significant
difference in aneurysm growth rate.
The results of multivariate linear regression anal-
ysis are shown in Table 3. In this analysis statin use,
age, gender, and aneurysm size at first presentation
were associated with a difference in AAA growth rate.
Statin users had a significant 1.16 mm lower annual
aneurysm growth rate compared to non-users (95% CI
0.33–1.99 mm/year). For each year increase of age at
first presentation the mean aneurysm size growth rate
was slowed by 0.09 mm (95% CI 0.03–0.14 mm/year).
Females had a significantly higher growth rate than
males (mean difference 1.82 mm/year, 95% CI 0.49–
3.15 mm/year). Aneurysm diameter at first presen-
tation also was independently associated with annual
aneurysm growth (0.06 mm/year increase per mm
difference in AAA size, 95% CI 0.01–0.11). We did not
find a significant influence of NSAID use, the presence
of COPD, diabetes mellitus, or intermittent claudica-
















Fig. 1. Difference in mean annual aneurysm growth rate
between statin users (2.0 mm/year) and non-users
(3.6 mm/year).Discussion
This study showed an association between statin use
and attenuation of infrarenal abdominal aortic aneur-
ysm growth, irrespective of other known factors
influencing aneurysm growth.
Statins frequently are prescribed to lower choles-
terol levels as large prospective studies have shown an
improved outcome in statin users, mainly by
reduction of late cardiac events.18–21 However, recentlyEur J Vasc Endovasc Surg Vol 32, July 2006other effects independent of serum cholesterol levels,
so-called pleiotropic or non-lipid lowering effects,
have been described. These recently described pleio-
tropic effects of statins might be related to the observed
attenuation of AAA growth.
The pathophysiology of aortic aneurysm develop-
ment, growth and eventually rupture is still not fully
understood. Inflammation responses aggravated by a
genetic susceptibility are probably important determi-
nants. Accumulation and activation of mononuclear
inflammatory cells; increased expression of proin-
flammatory cytokines, chemokines and matrix-
degrading proteinases; degradation of elastin and
collagen; oxidative and hemodynamic stress; and
depletion of smooth muscle cells seem all to play a
pivotal role.16 Some of these inflammatory responses
such as interleukin-6 and matrix metalloproteinases
(MMPs) could be assessed in animal aortic aneurysm
models, by inducing collagen and elastin degradation
Statins and AAA Growth Attenuation 25of the aortic wall. The response of interleukin-6 release
is also genetically determined as assessed by the
increased levels of interleukin-6 in patients with the
174G/C genotype.22 The combined effects of inflam-
matory response and genetic susceptibility in patients
with other environmental risk factors as elderly age
and smoking might be responsible for the develop-
ment and growth of AAA.
Recently, Steinmetz et al.16 have shown in a mice
model that statins suppress the development of
experimental AAAs. The positive effect of statins
was ascribed to its properties of preserving medial
elastin, smooth muscle cells, and beneficially altering
aortic wall expression of MMPs.16 Also other exper-
imental studies have confirmed these positive effects
of statins on MMPs.23–25 In a study by Wilson et al. of
63 infrarenal aortic biopsies obtained during AAA
repair the levels of MMP-9 and MMP-3 were
significantly lower in patients taking statins.15 The
reduced levels of MMP-9, achieved by inhibition of the
activation of neutrophils and macrophages, in statin
users was confirmed by Nagashima and co-workers.26
In our study age, gender, and aneurysm diameter at
first presentation were associated with a difference in
AAA growth rate. These results are in line with
previously reported studies on the influence of these
risk factors.27 In some studies smoking and diabetes
were found to have a significant impact on aneurysm
growth rate,27 however, we did not come across such
an association which may be related to the small
number of patients with diabetes. Therefore, a type II
error might have occurred. Since, this analysis is
retrospective, for smoking habits we had no infor-
mation on number of ‘pack years’ and current
exposure, i.e. number of cigarettes per day.
In the past several medical intervention trials for the
prevention of abdominal aneurysm expansion have
been reported. The propanolol trial investigators did
not find a growth benefit of propanolol use in a
double-blind randomized study in 358 patients.28 In a
double-blind randomized trial Vammen et al. showed
that macrolide antibiotic treatment for 4 weeks was
associated with a significant lower expansion rate
compared to placebo.29 Mosorin et al. also found a
significant lower expansion rate in patients taking
doxicyclin for a period of 3 months compared to
patients receiving placebo.30 These findings have been
confirmed by Baxter et al. in a phase II trial in 63
patients.31 Another therapeutic strategy for the pre-
vention of aneurysm growth is to intervene in the
inflammatory response present in aortic aneurysms. In
animal models as well as in a very small case control
study indometacin indeed seemed to prevent the
development and growth of abdominal aorticaneurysms.13,32 However, in the present study we
could not confirm this observation.
A major limitation of this analysis is the use of
ultrasonographic examinations for the measurement
of aortic diameter. The inter- and intra-observer
variability of this screening modality might influence
the outcome of any study based on this type of
measurement. However, as shown by Singh et al.
experienced ultrasonographers and radiologists
achieve a high degree of accuracy, which was
confirmed in the present study with a low inter- and
intra-observer variability.33 As all non-randomized
observational studies this study has some other
limitations as well. Though we included several
confounding factors in the multiple regression anal-
ysis some might have been missed. One of them could
be the potentially better blood pressure control in
statin users as significantly more statin users were on
angiotensin-II-antagonist therapy. Unfortunately, we
did not have accurate information on blood pressure
control during the study period. Also several other
questions could not be answered in this study due to
its retrospective nature and should be addressed in
future studies including the effect of statin therapy
duration on AAA growth and the time between statin
therapy initiation and reduction of AAA growth rate.
In conclusion, this study shows a clear association
between statin use and a decreased expansion rate of
infrarenal aortic aneurysms. This finding is in line
with experimental studies in mice and rats, but needs
to be confirmed by randomized clinical trials.Acknowledgements
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